A study published in the British Journal of General Practice titled "Overdiagnosis of asthma in children in primary care: a retrospective analysis" found that over half of children diagnosed with asthma at several major healthcare centers in the Netherlands probably do not have the disease. Researchers from Julius Health Care Center and University Medical Center … [Read more...] about Study shows significant overdiagnosis of asthma in children
News
Savara Pharmaceuticals raises $20 million for AeroVanc development
Savara Pharmaceuticals has announced the completion of a $20 million financing round to fund a pivotal Phase 3 clinical trial of its AeroVanc vancomycin DPI for the treatment of MRSA lung infections in cystic fibrosis patients. The company says that it expects enrollment for the study to begin by the end of the year. In February 2015, Savara announced positive … [Read more...] about Savara Pharmaceuticals raises $20 million for AeroVanc development
Impel NeuroPharma licenses intranasal therapy for depression
Intranasal delivery specialist Impel NeuroPharma and the Toronto-based Centre for Addiction and Mental Health (CAMH) have signed a licensing agreement for an intranasal neuropeptide-based therapy for the treatment of depression. The peptide, which was discovered at CAMH, will be delivered using Impel's Precision Olfactory Delivery (POD) device. According to CAMH, … [Read more...] about Impel NeuroPharma licenses intranasal therapy for depression
Alexza Pharmaceuticals signs non-binding letter of intent with Grupo Ferrer
Inhaled drug developer Alexza Pharmaceuticals has signed a non-binding letter of intent and entered into discussions with Grupo Ferrer regarding Ferrer's acquisition offer, the company said. Alexza noted that the letter of intent allows the company to continue to explore other options, and there is no guarantee that it will complete the deal with Ferrer. In … [Read more...] about Alexza Pharmaceuticals signs non-binding letter of intent with Grupo Ferrer
MannKind founder Alfred Mann has died at age 90
MannKind Corporation has announced the death of founder and Chairman Emeritus Alfred Mann at age 90, one week after he stepped down as Chairman of the Board. Mann served as CEO from November 2003 until January 2015 and as Chairman of the Board of MannKind from 2001 until last week. According to the company, Mann's death will have no effect on business activities or … [Read more...] about MannKind founder Alfred Mann has died at age 90
Curida announces alliance with OINDP consultant René Bommer
Norwegian CDMO Curida, which offers a wide range of analytical, development, and manufacturing services for OINDPs, has announced a new strategic partnership with pharmAccel Consulting Director René Bommer. In July 2015, Curida acquired a nasal spray manufacturing facility in Elverum, Norway from Takeda, and the company cites Bommer's expertise in nasal spray … [Read more...] about Curida announces alliance with OINDP consultant René Bommer
Adapt launches Narcan nasal spray in the US
Adapt Pharma has announced the availability of Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose in the US. Narcan nasal spray was approved by the FDA in November 2015. In 17 of the 50 US states, no prescription is required. According to Adapt, the nasal spray will be available at a discounted price of $37.50 per dose for government … [Read more...] about Adapt launches Narcan nasal spray in the US
Teva Canada launches tobramycin inhalation solution
Health Canada has approved Teva Canada Limited's application for its tobramycin inhalation solution, a generic version of Novartis's TOBI inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Canada. The Teva tobramycin inhalation solution is now available in Canadian pharmacies, the company said. Teva Canada Limited … [Read more...] about Teva Canada launches tobramycin inhalation solution
Aptar Pharma teams with Propeller Health on connected MDI
Propeller Health and Aptar Pharma have teamed up to develop a connected MDI that features an integrated sensor and an electronic dose counter. The companies say that they expect to begin clinical studies with the inhaler by the end of 2016 and that they are looking to license the device. The Propeller inhaler tracking platform has received 510(k) clearance from … [Read more...] about Aptar Pharma teams with Propeller Health on connected MDI
Astech Projects acquired by Schauenburg International Group
Laboratory automation company Astech Projects has been acquired by German holding company the Schauenburg International Group. Astech Projects manufactures the Xelair, Xelize, and Xelox ranges of automated inhaler testing systems and offers systems for nasal spray and blister strip testing as well. According to the announcement, all of the management and … [Read more...] about Astech Projects acquired by Schauenburg International Group